HEMOGENYX PHARMACEUTICALS PLC

Regulatory Filings • Nov 20, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9031W

Hemogenyx Pharmaceuticals PLC

20 November 2017

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

University of Oxford Collaboration

Collaboration promises to 'turbo-charge' development of blood cancer treatments

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), a biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, has entered into a collaboration with the University of Oxford to test new means of accelerating and improving the process by which transplanted blood stem cells grow and make healthy blood cells.

Hemogenyx will leverage the experience of researchers at the University of Oxford in administering certain biologics to stem cells to attempt to accelerate and improve the engraftment of hematopoietic stem and progenitor cells in animal models. Engraftment is the process by which blood stem cells integrate into the bone marrow and make healthy blood. If successful, this approach has the potential to dramatically improve the efficiency and safety of bone marrow transplants.

Hemogenyx also will test whether this approach facilitates the conversion of Human Post-natal Hemogenic Endothelial Cells (Hu-PHEC), Hemogenyx's proprietary source of blood stem cells, into fully functional, transplantable blood stem cells. Hu-PHEC generate cancer-free, patient-matched blood stem cells and are the basis of Hemogenyx's cell therapy product. Using Hu-PHEC, Hemogenyx intends to revolutionize bone marrow transplants, improving the efficacy of the therapy and potentially eliminating the need to find a matching bone marrow donor, a problem that the majority of patients who need allogeneic bone marrow transplants currently face.

Blood cancers affect more than 1.1 million people in the United States each year and it is estimated that 171,500 new patients were diagnosed with blood cancer in 2016. Currently, up to 60% of patients who need allogeneic bone marrow transplants are unable to find a donor match for the procedure, and, for those who do manage to identify a donor, up to 50% of bone marrow transplants fail due to the body's rejection of the transplant, complications from the procedure or a relapse of the disease. Hemogenyx seeks to fundamentally change how bone marrow transplantation is performed and allow more people who need transplants to be able to obtain them by eliminating the need for a donor and improving their efficacy.

Professor Jagdeep Nanchahal at the University of Oxford, who is leading the Oxford team in the collaboration with Hemogenyx, said: "I'm excited to be partnering with Hemogenyx on their ground-breaking medical research. The in-vivo tests Hemogenyx is about to conduct have the potential to improve stem cell engraftment for patients suffering from blood cancers."

Dr. Vladislav Sandler, CEO of Hemogenyx, said: "The collaboration between Hemogenyx and the University of Oxford promises to completely transform the treatment of blood cancers and turbo-charge the development of Hemogenyx's Hu-PHEC technologies. By pairing Oxford's established science and know-how with Hemogenyx's advanced technologies, we are moving closer to developing reliable products that will eventually save lives."

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Dr Robin Campbell, Chairman
Optiva Securities Ltd		Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP		Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

About Prof. Nanchahal

Jagdeep Nanchahal is a surgeon scientist with a particular interest in translating discoveries from the lab through to early clinical trials.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFLSLSLALID